AI assistant
Sending…
REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2017
Aug 11, 2017
29977_dirs_2017-08-11_47cdde1b-d8bd-4a85-a09c-bfd15a31b5b1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2017-08-10
Reporting Person: Terifay Robert J (EVP Commercial)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-08-10 | Common Stock | M | 1921 | $52.03 | Acquired | 25214 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-08-10 | Incentive Stock Option (right to buy) | $52.03 | M | 1921 | Disposed | 2021-12-16 | Common Stock (1921) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 1699 | Indirect |
Footnotes
F1: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.
More from REGENERON PHARMACEUTICALS, INC.
Regulatory Filings
2026
May 8
Major Shareholding Notification
2026
Apr 30
Interim / Quarterly Report
2026
Apr 29
Regulatory Filings
2026
Apr 29
Annual Report
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Regulatory Filings
2026
Apr 8
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 3